Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare : a plain language summary

Share

Abstract

Plain Language Summary: What is this summary about? This summary describes results from a real-world study called the Transthyretin Amyloidosis Outcomes Survey (THAOS for short). In this study from THAOS, researchers looked at people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM for short). Some people from this study took an approved treatment for ATTR-CM called tafamidis and some did not. Researchers looked at how many people with ATTR-CM were alive after two and a half years and three and a half years. They also looked at the side effects people had when they took tafamidis. What are the key takeaways? In people who took tafamidis, an estimated 8 in 10 people (84%) were alive after two and a half years, and an estimated 8 in 10 people (77%) were alive after three and a half years. In people who did not take tafamidis, an estimated 7 in 10 people (70%) were alive after two and a half years, and an estimated 6 in 10 people (59%) were alive after three and a half years. The side effects people had while taking tafamidis in the THAOS study were similar to what has been reported in clinical studies. What were the main conclusions reported by the researchers? This real-world study supports the use of tafamidis for improving survival in people with ATTR-CM This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text.